Goldman Sachs Group Analysts Give Roche (ROG) a CHF 325 Price Target
ROG has been the subject of several other research reports. Deutsche Bank set a CHF 255 target price on shares of Roche and gave the stock a neutral rating in a report on Monday, September 11th. Berenberg Bank set a CHF 260 target price on shares of Roche and gave the stock a neutral rating in a report on Tuesday, October 24th. J P Morgan Chase & Co reaffirmed a buy rating on shares of Roche in a report on Monday, October 9th. Morgan Stanley set a CHF 260 target price on shares of Roche and gave the stock a neutral rating in a report on Friday, October 6th. Finally, Jefferies Group set a CHF 295 target price on shares of Roche and gave the stock a buy rating in a report on Monday, October 16th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average target price of CHF 261.32.
Roche (ROG) opened at CHF 240.50 on Thursday. Roche has a 1-year low of CHF 219.10 and a 1-year high of CHF 273.
Roche Company Profile
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.